- Home
- PLRX vs ALXO Comparison
PLRX vs ALXO Comparison
Compare PLRX & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- ALXO
- Stock Information
- Founded
- PLRX 2015
- ALXO 2015
- Country
- PLRX United States
- ALXO United States
- Employees
- PLRX N/A
- ALXO N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- PLRX Health Care
- ALXO Health Care
- Exchange
- PLRX Nasdaq
- ALXO Nasdaq
- Market Cap
- PLRX 90.9M
- ALXO 28.3M
- IPO Year
- PLRX 2020
- ALXO 2020
- Fundamental
- Price
- PLRX $1.45
- ALXO $0.46
- Analyst Decision
- PLRX Hold
- ALXO Strong Buy
- Analyst Count
- PLRX 10
- ALXO 6
- Target Price
- PLRX $9.79
- ALXO $4.14
- AVG Volume (30 Days)
- PLRX 744.6K
- ALXO 522.3K
- Earning Date
- PLRX 05-20-2025
- ALXO 05-08-2025
- Dividend Yield
- PLRX N/A
- ALXO N/A
- EPS Growth
- PLRX N/A
- ALXO N/A
- EPS
- PLRX N/A
- ALXO N/A
- Revenue
- PLRX N/A
- ALXO N/A
- Revenue This Year
- PLRX N/A
- ALXO N/A
- Revenue Next Year
- PLRX N/A
- ALXO N/A
- P/E Ratio
- PLRX N/A
- ALXO N/A
- Revenue Growth
- PLRX N/A
- ALXO N/A
- 52 Week Low
- PLRX $1.10
- ALXO $0.44
- 52 Week High
- PLRX $16.52
- ALXO $17.50
- Technical
- Relative Strength Index (RSI)
- PLRX 41.87
- ALXO 36.09
- Support Level
- PLRX $1.36
- ALXO $0.44
- Resistance Level
- PLRX $1.72
- ALXO $0.55
- Average True Range (ATR)
- PLRX 0.11
- ALXO 0.05
- MACD
- PLRX 0.04
- ALXO 0.00
- Stochastic Oscillator
- PLRX 29.17
- ALXO 13.29
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.